Rationale for off-label treatments use in primary progressive multiple sclerosis: A review of the literature - 22/11/22
, X. Moisset b, P. Clavelou bAbstract |
Background |
Until recently, few therapeutic options, other than symptomatic treatment, were available for patients with primary progressive multiple sclerosis (PPMS). Ocrelizumab is the only approved treatment in this indication, and only since 2017. However, many patients in France are receiving off-label treatments for PPMS, mainly rituximab, mycophenolate mofetil, methotrexate, cyclophosphamide, and azathioprine.
Objective |
To evaluate published data concerning the efficacy of these five treatments frequently used as off-label disease-modifying therapies.
Methods |
We reviewed and summarized the studies published in Pubmed since the inception of the database.
Results |
Evidence from randomized controlled trials is lacking to support the use of these treatments as disease-modifying therapies in PPMS.
Conclusion |
The literature lacks dedicated studies to support the off-label use of these disease-modifying therapies in PPMS. However, some limited data are available in the literature suggesting that the use of rituximab and cyclophosphamide could potentially be of some interest in specific subpopulations.
Le texte complet de cet article est disponible en PDF.Keywords : Multiple sclerosis, Primary progressive multiple sclerosis, Treatment, Off-label use
Plan
Vol 178 - N° 9
P. 932-938 - novembre 2022 Retour au numéro
Article précédent
- Patients with Parkinson's disease and a history of falls have decreased cerebellar grey matter volumes in the cognitive cerebellum
- N. Morelli
- From cryptogenic to ESUS: Toward precision medicine?
- S. Timsit
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?